Introduction
Patients with advanced stage nonesmall-cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs). However, brain metastases (BMs) occur frequently and contribute significantly to disease-related morbidity and mortality, and hence, constitute a critical therapeutic challenge in oncology. The central nervous system represents a sanctuary site as TKI efficacy is limited here owing to restricted penetration of the blood-brain barrier. 1, 2 Though limited, intracranial responses are nevertheless particularly seen in patients receiving EGFR TKI therapy. 3 Hence, the intracranial efficacy of TKI therapy is
Clinical Practice Points
Brain metastases emerge frequently in metastatic none small-cell lung cancer (NSCLC). This technique has a high availability and an excellent spatial resolution, but, especially in gliomas, the ability to accurately define the tumor volume and quantify the burden of disease is limited. [5] [6] [7] Furthermore, following neuro-oncological treatment such as resection and radiotherapy as well as drug treatment for primary and secondary brain tumors (eg, alkylating chemotherapy, immunotherapy), can lead to reactive and benign MRI signal changes (eg, hyperintensities on T2 or fluid attenuation inversion recovery sequences or an increase of the contrast enhancement extent), which are difficult to discern from true tumor progression. [8] [9] [10] Clinically, these reactive treatment-related changes, frequently named pseudoprogression, are of considerable importance because an effective treatment might be erroneously terminated too early with potentially negative influence on survival. Furthermore, these MRI signal alterations may also occur owing to demyelination, ischemia, and infection/inflammation. 
Case Report
A 44-year-old female patient (50 pack-years) presented with a tumor in the right upper lobe of the lung and metastases in mediastinal lymph nodes, thoracic vertebrae 9-11, and 9 infra-and supratentorial BMs, with the largest BM measuring 19 mm in diameter in the left frontal lobe (cT3 cN2 cM1b, UICC stage IV) (Figure 1 ). Biopsy revealed a highly differentiated, thyroid transcription factor1-positive adenocarcinoma of the lung. The patient received 1 cycle of cisplatin/pemetrexed prior to molecular diagnostics and refused both further chemotherapy and whole-brain radiation (WBR) of the BM.
Next-generation sequencing (NGS) of the biopsy specimen demonstrated an unusual EGFR double mutation partly affecting the activating loop on exon 21, p.L858R, beside a p.A859S mutation of unknown significance (p.[L858R;A859S]). Although imaging scans of the brain showed rapid progression of BM, the patient still refused WBR. An interdisciplinary tumor board suggested treatment with erlotinib with close monitoring. After informed patient consent, erlotinib treatment was initiated immediately (150 mg/d).
Extracranial therapy response was monitored using serial whole body FDG-PET/computed tomography scans. BMs were monitored by both serial standard MRI and FET-PET scans. After 2 weeks of erlotinib treatment, PET imaging showed significant reductions in metabolic activity in extracranial lesions as well as in BMs (Table 1) , indicating response (Figure 1, time points t1, t2) . Six weeks later, tracer uptake of the left frontal lesion further decreased as compared with time point t2 (SUV max decrease, 13%) ( Table 1 ). In contrast, MRI scans did not show further shrinkage of the left frontal contrast-enhancing lesion (Figure 1, time point t2,  t3) . The extracranial metabolic activity as assessed by FDG-PET remained very low. The patient finally agreed to palliative radiotherapy of the vertebral bone metastases, leading to a complete metabolic response in this tumor site (Figure 1, time point t4) .
After 23 weeks of erlotinib therapy, FET-PET revealed, in line with the brain MRI, an increased metabolic activity in the left frontal lobe (Table 1 and Figure 1 , time point t4), indicating tumor progression. Conversely, extracranial metabolic activity determined by FDG-PET remained low with no signs of progressive disease according to the PET Response Criteria in Solid Tumors (PER-CIST) (Figure 1, time point t3, t4) . A stereotactic biopsy of the progressive left frontal brain metastasis confirmed NSCLC histology and persistence of the EGFR p.[L858R;A859S] double mutation, with no detection of a resistance mechanism such as EGFR T790M mutation, MET, or HER2 amplification nor any other relevant genetic mutation in our 14 gene NGS panel. The patient subsequently received brachytherapy of the left frontal lesion using iodine-125 seeds 15 and WBR owing to further extensive intracranial tumor progression with detection of over 50 new supra-and infratentorial BMs. Hereafter, the patient received erlotinib 300 mg/d and died 22 months later.
Conclusion
Our case suggests the diagnostic potential of FET-PET for the assessment of early response and disease progression of BMs in EGFRmutated NSCLC treated with TKI therapy. Although FDG-PET was useful in repeatedly monitoring extracranial tumor response, FET-PET was of superior diagnostic value in assessment of intracranial response. In contrast to MRI, FET-PET in our patient even seemed to be a more sensitive diagnostic imaging technique for detection of early response of BMs during treatment before morphologic changes became evident in contrast-enhanced MRI. Nevertheless, the strong progression in BMs in our patient was also detectable by MRI, and smaller lesions could not be detected in FET-PET.
The lack of an identified mode of acquired resistance to EGFRtargeted therapy underlines the need for proper diagnostic tools in the assessment of intracranial therapy response. Our observations suggest that FET-PET might be a highly sensitive and effective imaging technique and moreover, might add functional insights to standard MRI scans in monitoring BMs. Further clinical 
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investigation of the diagnostic significance of FET-PET, especially regarding response evaluation of targeted therapy in tumor brain metastases, is warranted.
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